(509) 228-1000 WA
(208) 754-3100 ID

Clinical Studies

TRIAL NUMBER - NCT03901963

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation flow (NGF) or next generation sequencing (NGS) following high-dose therapy (HDT) and autologous stem cell transplant (ASCT), with or without consolidation therapy.

 
I Want to Participate

Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician. 

View Trial

For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at research@ccnw.net for more information. Be sure to include:

  • Your name
  • Phone number & if we can leave a voice message at this number
  • Trial number(s) you are interested in
  • Name and city of clinic you are currently being treated